title: [Uroinfections and the possibilities of therapy with levofloxacin].
abstract: The common occurrence, of inflammatory diseases in the urinary tract and the genitals in men, is quite a reason for identification of the agents and looking for some new chances of therapeutic treatment.
  
  
  METHODS
  For a period of two years (2002-2003) we accomplished 4810 microbiological tests of urine and prostate secretion on patients with uroinfections. The cultures are completed on standard nutrition medium, as the biochemical identification of the strains is accomplished by the systems mini API and "bio Merieux" BBL Crystal, "Becton Dickinson". Meanwhile for a period of one year, 113 patients with different uroinfections are treated and studied. In 16 (14.1%) Levofloxacin (Tavanic-R) is applied i.v. 500mg/daily as in the rest cases 97 (85.9%) Tavanic are applied per oral in different therapeutic doses.
  
  
  CONCLUSIONS
  The most common agent in our study was the E. Coli, as for the year 2003 we read an increase of the infections caused by E.Coli with 3.4% comparing to the previous one (38.5% to 35.1%). The differentiation of patients treated with Levofloxacin in groups is completed as follows: with acute uncomplicated cystitis--pyelonephritis after ESWL--15.9%; with postoperative uroinfections--20.3%; with chronic post-tuberculosis pyelonephritis--4.4%; and with inflammatory diseases of the male genitals--37.2%.
authors.forename: Ch
authors.initials: Ch
authors.lastname: Slavov
authors.forename: B
authors.initials: B
authors.lastname: Markova
authors.forename: N
authors.initials: N
authors.lastname: Bovianska
authors.forename: Iu
authors.initials: Iu
authors.lastname: Proevska
authors.forename: I
authors.initials: I
authors.lastname: Chukov
authors.forename: P
authors.initials: P
authors.lastname: Panchev
mesh_terms: D000892:Anti-Infective Agents, Urinary / Q000008:administration & dosage / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D005832:Genital Diseases, Male / Q000188:drug therapy / Q000382:microbiology; D006801:Humans; D064704:Levofloxacin; D008297:Male; D015242:Ofloxacin / Q000008:administration & dosage / Q000627:therapeutic use*; D016896:Treatment Outcome; D014552:Urinary Tract Infections / Q000188:drug therapy* / Q000382:microbiology; D014556:Urine / Q000382:microbiology*
chemical_list: D000892:Anti-Infective Agents, Urinary; D064704:Levofloxacin; D015242:Ofloxacin